Leading the TCR T-Cell Therapy Space

Transforming cancer immunotherapy with affinity enhanced T-cell receptors.

Adaptimmune, a leader in T-cell therapy to treat cancer, has multiple trials ongoing in both solid tumours and hematologic cancer types, and in cancers where survival rates for patients can be very limited. Our T-cell therapies have already shown preliminary evidence of tumor reduction in patients and also show a promising risk/benefit profile.

Developed over the last 15 years, our proprietary our proprietary SPEAR® (Specific Peptide Engineered Affinity Receptor) T-cell engineering platform has generated a strong pipeline of affinity enhanced T-cell therapies. We use these therapies to harness the body’s own immune system to find and destroy diseased cells. We can develop T-cell therapies for a broad spectrum of cancer types and patients and have multiple T-cell therapies in development and/or in clinical trials.

Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality.

Company History

  • 1993-1999

    TCR technology developed at Oxford University

  • 1999

    Avidex was formed on the basis of T cell receptor technology from Oxford University

  • 2006

    Avidex was acquired by Medigene

  • 2008

    Adaptimmune spun out as a virtual company with University of Penn collaboration

  • 2011-2014

    Adaptimmune establishes R&D infrastructure and delivers promising clinical data

  • 2014

    Strategic collaboration with GSK + $104m Series A Funding Round

  • 2015

    Adaptimmune IPO on NASDAQ raises $176 million.